Application of leukocyte cell population data parameters in evaluating the severity and prognosis of acute pancreatitis

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000038926

Enrollment

Unknown

Registered

2020-10-10

Start date

2020-11-20

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatitis

Interventions

group by the severity of pancreatitis:Nil

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 and <= 90 years; 2. If they are women in childbearing period, they should contraception at least one month before screening, and promise to take contraception during the whole study period and continue to the specified time after the end of the study; 3. Within 72 hours after onset of the disease; 4. The diagnosis of acute pancreatitis was consistent with the following 2 items; (1) Abdominal pain: acute attack of persistent, severe abdominal pain, often radiated to the back; (2) Serum lipase activity (or amylase) was at least 3 times higher than the upper limit of normal value; (3) CT or MRI showed the characteristic changes of acute pancreatitis. 5. All the patients signed the informed consent of the study.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Severe chronic failure of heart, liver, lung, kidney and blood system existed before admission; 3. Cancer without cure; 4. Autoimmune disease or immunosuppression (previous solid organ or bone marrow transplantation, AIDS, long-term use of immunosuppressants or hormones, etc.) 5. Suffering from diseases of the blood system or affecting the morphology of blood cells.

Design outcomes

Primary

Measure	Time frame
Severity of acute pancreatitis;SOFA score;APACH II score;leukocyte cell population data, CPD;Blood cell analysis;Liver function index;Renal function index;Marshall score;BISAP score;Balthazar CT socre;days in hospital;Prognosis;	—

Secondary

Measure	Time frame
Serum amylase;Blood gas analysis;temperature;heart rate;blood pressure;triglyceride;Coagulation function index;C-reactive protein;Procalcitonin;NT-proBNP;Myocardial protein;Immune function index;Inflammatory cytokines;Humoral immunity index;Local complications;	—

Countries

China

Contacts

Public ContactEnqiang Mao

Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine

maoeq@yeah.net+86 13501747906

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026